000	02255cam  2200325zi 4500
001	9.940342
003	CaOODSP
005	20240712142618
006	m     o  d f
007	cr |n|||||||||
008	240709s2019    oncd    o    f00| 0 eng d
040	|aCaOODSP|beng|erda|cCaOODSP
043	|an-cn---
086	1 |aH14-635/2019E-PDF
245	00|aWhat we heard report - stakeholder consultation on the naming of biologic drugs.
264	1|a[Ottawa] : |bHealth Canada = Santé Canada, |c[2019]
300	|a1 online resource (8 pages) : |bchart
336	|atext|btxt|2rdacontent
337	|acomputer|bc|2rdamedia
338	|aonline resource|bcr|2rdacarrier
500	|aIssued also in French under title: Rapport « Ce que nous avons entendu » – consultation auprès des intervenants sur l’attribution de noms aux médicaments biologiques.
520	|a"Health Canada and the Institute for Safe Medication Practices (ISMP) Canada conducted an online consultation on the naming of biologic drugs from January 18 to February 9, 2018. With the entry of biosimilars into the Canadian market, the number of biologic drugs sharing a nonproprietary (common) name is increasing. The objectives of the consultation were (1) to seek stakeholder views on whether Health Canada’s current approach to biologics naming is adequate or, if not, which alternate proposed option would be most appropriate to distinguish among biologics that share the same non-proprietary name, and (2) to better understand the impact of implementing each proposed option on external stakeholders"--Introduction, page 2.
650	0|aBiologicals|zCanada|xPublic opinion.
650	0|aDrugs|xLabeling|zCanada|xPublic opinion.
650	0|aPublic opinion|zCanada.
710	1 |aCanada. |bHealth Canada, |eissuing body.
775	08|tRapport « Ce que nous avons entendu » – consultation auprès des intervenants sur l’attribution de noms aux médicaments biologiques.|w(CaOODSP)9.940547
856	40|qPDF|s593 KB|uhttps://publications.gc.ca/collections/collection_2024/sc-hc/H14-635-2019-eng.pdf
856	4 |qHTML|sN/A|uhttps://www.canada.ca/en/health-canada/services/publications/drugs-health-products/naming-of-biologics-what-we-heard.html